Research Article

Quercetin Inhibits KBM7R Cell Proliferation through Wnt/β-Catenin Signaling

Wei Li, Yang Yu, Huanchen Cheng, Shengwei Liu, Tiejun Gong, Jun Ma, and Qinghua Tang

Institute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin 150010, Heilongjiang, China

Correspondence should be addressed to Qinghua Tang; tangqinghua@hrbsdyy.com.cn

Received 6 May 2022; Revised 24 May 2022; Accepted 7 June 2022; Published 24 June 2022

Academic Editor: Muhammad Zia-Ul-Haq

Copyright ©2022 Wei Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Tyrosine kinase inhibitors could treat chronic myelogenous leukemia (CML) effectively, but they have no effect on patients with T315I mutation. It is necessary to find drugs to overcome the resistance. Quercetin (Qu) is a kind of bioflavonoid with an antitumour effect. In this study, we observed the effect of Qu on proliferation and Wnt/β-catenin pathway in KBM7R cells, an imatinib-resistant cell with T315I mutation. Methods. The IC_{50} of Qu was detected by trypan blue staining. The KBM7 cell apoptosis and cycle were detected through the method of flow cytometry (FCM). The expression of the related mRNA and protein was evaluated by means of an RT-PCR assay and western blot in KBM7 (sensitive to IM) and KBM7R cells. Results. These results showed that in the KBM7R cell, the proliferation inhibition effect was increased after 48 h administration with different Qu concentrations. The IC_{50} to Qu was 241.7 μmol/L. The different doses of Qu (50, 100, and 200 μmol/L) would raise apoptosis and depress the cell cycle at the G1 phase. Dealing with a median Qu concentration (100 μmol/L) for 48 h, the mRNA and the protein level of caspase-3, caspase-8, and caspase-9 along with p21 and p27 raised compared with the control. The median concentration of Qu could inhibit both the mRNA and protein levels of GSK-3β, β-catenin, and Lef-1 in the Wnt/β-catenin signal pathway and also the downstream targets PPAR-δ and cyclin D1 in both KBM7 and KBM7R cells. Conclusions. Our findings suggest that Qu could inhibit proliferation, induce apoptosis, and arrest the cell cycle on IM-resistant KBM7R cells with T315I mutation. And this effect could be related with the inhibition of the Wnt/β-catenin signal pathway and downstream targets.

1. Introduction

CML (chronic myelogenous leukemia) is a disease with a myeloproliferative disorder in hematopoietic stem cells, and its character shows the expression of the BCR-ABL fusion oncprotein and the Philadelphia chromosome [1]. Imatinib (IM), a tyrosine kinase inhibitor (TKI), has changed CML therapy. But due to the occurrence of BCR-ABL kinase mutations, such as Y253 H, E255 K, F359 V, G250 E, F317 L, E355 G, H396 P, T315I, and so on, which are related with drug resistance, limits the therapy [2]. The new-generation TKI, dasatinib, nilotinib, and bosutinib still have fewer effects on CML patients with T315I mutation. And clinical scientists are able to overcome the drug resistance caused by T315I mutation for the moment.

Quercetin (Qu) is a natural and bioactive flavonoid compound which has multiple pharmacological actions. Previous studies show that Qu is proposed as a potential anticancer agent. Qu combination with other drugs has been used in treatment of several cancers in order to obtain synergistic effects and reduce side effects [3]. We take the CML cell line KBM7R, with T315I mutation and resistance to IM as the object and observe the action of Qu on multiplication, apoptosis, and cell cycle, and analyze the Wnt/β-catenin signaling change.

2. Methods

2.1. Cell Lines and Culture Conditions and Agents. The KBM7R cells with the T315I mutant CML cell line (Human)
provided by Harbin Institute of Hematology and Tumor (Harbin, China) were cultured in a 1640 medium (Gibco, New York, USA) in an incubator containing 10% FBS at 37°C with 5% CO₂. Quercetin was provided by Sigma (St. Louis, MO, USA). It was dissolved into dimethyl sulphoxide (DMSO) to the final concentration of 20 mmol/L and preserved at −20°C.

2.2. Cell Proliferation Assay with Trypan Blue Test. About $2 \times 10^6$ KBM7R cells per well were seeded into 96-well plates in triplicate. Cells were incubated for 48 h with different concentrations of Qu from 5 μmol/L to 320 μmol/L. The trypan blue assay detected cell viability. Nonviable cells showed a blue stain. The following formula was calculated for cell viability: cell viability = (viable cell number in the experimental group/viable cell number in the DMSO group) × 100%. This experiment was performed three times. The IC₅₀ of Qu was calculated by GraphPad Prism software.

2.3. Apoptosis and Cell Cycle Detection. The culture dish with approximately $2 \times 10^6$ KBM7R cells was managed and supplemented with DMSO (1%, v/v) for 48 h as a control and different concentrations of quercetin (50 μmol/L, 100 μmol/L, and 200 μmol/L), respectively. Then these cells were collected and prepared for apoptosis and cell cycle assay. Flow cytometry assay was performed as described previously [4].

2.4. Western Blotting. Approximately $2 \times 10^6$ cells were managed for 48 h at the concentration of 100 μmol/L quercetin. Western blotting was performed as described previously [4]. Antibodies against GSK-3β/p-GSK-3β, β-catenin/p-β-catenin, Lef-1, cyclin D1, and BCR-ABL/p-BCR-ABL were provided from Santa Cruz company (CA, USA), PPAR-δ from Millipore (Boston, USA), caspase-3, caspase-8, and caspase-9 from BioVision (San Francisco, USA), P21 and P27 from Cell Signaling Technology (Danvers, USA), and β-actin from HaiGene company (Heilongjiang, China).

2.5. PCR and Primer. Approximately $2 \times 10^6$ KBM7R cells were dealt with quercetin (100 μmol/L) in the culture dish for 48 h. According to the product protocol, the total RNA was extracted and the quantitative RT-PCR experiment was performed. The 2−ΔΔCt method was used to perform a relative quantitative assay in triplicate. The real-time fluorescence quantitative PCR was used to evaluate the BCR-ABL copy as described previously [4]. Table 1 shows the primers sequence.

2.6. Statistical Assay. Both statistical assays were performed by SPSS 16.0 software. These data were shown as mean ± standard deviation. Student’s t-test analyzed significance, and P values (<0.05) showed statistical significance.

### Table 1: The primer sequence (5′–3′).

| Primer sequence (5′–3′) | Gene Name |
|-------------------------|-----------|
| GSK-3β F GTGATCCACACCGGGTG | GSK-3β |
| R CTGGTGCTACACTAAGTCCT | |
| R GGTTGGCGACATATGCAGCT | GSK-3β |
| β-Catenin R CAAATGCAGGTCTCATTC | β-catenin |
| Lef-1 F GACGAGGAGATAGTCC | Lef-1 |
| F TGTCGGCACCTGTGTCGTC | |
| PPAR-δ F GTGATCCACACCGGGTG | PPAR-δ |
| R CTGGTGCTACACTAAGTCCT | |
| Cyclin D1 R CTCCCTGGACCTCTGTC | Cyclin D1 |
| F TGTGTTGACCCCTTTCCT | |
| β-Actin R CACCTCCAGGTTCCAGT | β-Actin |

![Figure 1](image_url) Qu inhibits the proliferation of KBM7R cells.

### 3. Results

3.1. Quercetin Had Impact on Proliferation and Apoptosis and the Cell Cycle. The trypan blue assay results showed that different concentrations of Qu could inhibit the proliferation (Figure 1), and IC₅₀ was 241.7 μmol/L after calculation. After administration of 50, 100, and 200 μmol/L Qu, the KBM7R apoptosis rates were 12.37%, 31.43%, and 42.41%, respectively (Figure 2(a)). These apoptosis-related gene caspase-3, caspase-8, and caspase-9 mRNA expression ascended compared with the control. And their protein expression also increased (Figures 2(b) and 2(c)). 50, 100, and 200 μmol/L of Qu arrested cell cycle at the G1 phase, and the percentages were 51.54%, 61.29%, and 67.86%, respectively (Figure 3(a)). Compared with the control, Qu could promote the mRNA expression of P21 and P27 protein expression increased (Figures 3(b) and 3(c)).

3.2. Quercetin Could Inhibit Wnt/β-Catenin Signaling. In both KBM7 and KBM7R cells, we found that after administration of 100 μmol/L Qu for 48 h, the mRNA expression of the member and the target of Wnt/β-catenin signaling, GSK-3β, β-catenin, Lef-1, PPAR-δ, and cyclin D1 all decreased compared with the control (P < 0.01) (Figure 4(a)). Their corresponding protein level all decreased (Figure 4(b)). Therefore, it indicated that Qu could inhibit the Wnt/β-catenin signal.
3.3. Quercetin Could Decrease the mRNA Expression of BCR-ABL. We also detected the BCR-ABL expression in both KBM7 and 7R cells. Qu (100 μmol/L) could make about 30% cut of BCR-ABL mRNA expression (P < 0.05) in two cell lines (Figure 5(a)). But the BCR-ABL and phosphorylated protein had no obvious change (Figure 5(b)).

4. Discussion
Qu is an inhibitor of Wnt/β-catenin signaling [5], which play a vital function in tumor initiation and progression [6]. Increasing research shows that Wnt/β-catenin pathway dysregulation is involved with the development
and progression of hematological malignancies. This signaling has a strong relation with self-renew and maintenances CML stem/progenitor cells [7, 8] and also plays a role in the CML blastic phase [9]. In view of this pathway function, it would become a potential target for CML treatment [10]. The current and common CML cell lines for research include K562, KBM5, KBM7, and homologous drug-resistant cells. The resistance to IM cells K562R and KBM5R were induced by low-dose IM gradually, and KBM7R cells were carried with T315I mutation. The cells K562/K562 R are frequently used. The current research reported that the IC$_{50}$ of KBM7 was

![Figure](image_url)

**Figure 3:** Qu arrested KBM7R cells at the G1 phase.
Figure 4: Qu inhibited Wnt-β-catenin signaling.

Figure 5: The effect of Qu on BCR-ABL expression.
0.3 μmol/L and IC_{50} of KBM7R for IM was 5 μmol/L, respectively [11]. Our results showed that IC_{50} of KBM7 and KBM7R was 0.28 μmol/L and 4.71 μmol/L, respectively. Accordingly, the IM resistance time was about 17 and similar to previous reports. So KBM7R is considered to be an appropriate cell drug resistance model for study. Our previous study has confirmed that Qu has inhibited the proliferation on KBM7 cell [4] and the IC_{50} of Qu was 107.6 μmol/L. This study showed that the IC_{50} of Qu was 241.7 μmol/L in the KBM7R cells. Therefore, the resistance time was 2.25. Compared with IM, Qu could improve the resistance greatly. Qu also induces the apoptosis of KBM7R in a dose-dependent manner, and it might be related with the increased caspase-3, caspase-8, and caspase-9 levels.

The transcription factor β-catenin is the pivotal component which is mediated by GSK3β for Wnt/β-catenin cascade. Subsequently, β-catenin interacts with Lef-1 to trigger the signal target genes such as PPAR-δ and cyclin D1. These results showed that Qu could inhibit this signal, and the gene and protein expression of cascade members were decreased in both sensitive and resistant cells. PPAR-δ is one of the targets of Wnt signaling and plays an important role in tumor proliferation [12]. Some studies reported that PPAR-δ expression increased in some solid tumors, such as colon cancer [13] and skin cancer [14], but the PPAR-δ action is not clear in CML so far. After administration of Qu, the PPAR-δ expression decreased, so it could be related with proliferation inhibition. Another target, cyclin D1, which is a key cell cycle regulator, has a crucial effect in cancer growth. Cyclin D1 decreased after administration of Qu and simultaneously P21 and P27 protein expressions increased. It suggests that these genes take part in cell cycle arrest.

5. Conclusion

Briefly, Qu could inhibit the proliferation of IM-resistant KBM7R cells and reduce the resistance. Moreover, the apoptosis increased and the cell cycle was arrested in the G1 phase. Meanwhile, Qu inhibited the Wnt/β-catenin signal pathway members’ expression in both sensitive KBM7 and resistant KBM7R cells. Then, the expression of PPAR-δ and cyclin D1, the downstream targets of this signaling, and BCR-ABL gene expression were also reduced in both cells. The suppressed pathway might be involved in the effect of overcoming IM resistance. In this study, we only found the inhibition effect of Qu on CML in vitro, and its action should be testified in vivo in future. Moreover, the possibility would be investigated that Qu combined with chemotherapy drugs had a synergistic reaction and decrease the side effects.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Disclosure

This paper has been previously submitted to the conference as per the URL: http://www.kgtsg.com/conference/5726eca0c094165d30136bbd3384bd37.html.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] P. Xin, C. Li, Y. Zheng et al., “Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines,” *Drug Design, Development and Therapy*, vol. 11, no. 11, pp. 1115–1126, 2017.

[2] T. V. Pospelova and V. A. Pospelov, “Latest progress in tyrosine kinase inhibitors,” *Oncotarget*, vol. 5, no. 5, pp. 1157–1161, 2014.

[3] A. Brito, M. Ribeiro, A. Abrantes et al., “Quercetin in cancer treatment, alone or in combination with conventional therapeutic?” *Current Medicinal Chemistry*, vol. 22, no. 26, pp. 3025–3039, 2015.

[4] W. Li, Y. Zhao, B. Tao, and Y. Zhang, “Effects of quercetin on hedgehog signaling in Chronic myeloid leukemia KBM7 cells,” *Chinese Journal of Integrative Medicine*, vol. 20, no. 10, pp. 776–781, 2014.

[5] M. Mosjin, J. M. Vicentic, M. Schwirtlich, V. Topalovic, and M. Stevanovic, “Quercetin reduces pluripotency, migration and adhesion of human teratocarcinoma cell line NT2/D11 by inhibiting Wnt/β-catenin signaling,” *Food & Function*, vol. 5, no. 10, pp. 2564–2573, 2014.

[6] N. Krishnamurthy and R. Kurzrock, “Targeting the Wnt/β-catenin pathway in cancer: update on effectors and inhibitors,” *Cancer Treatment Reviews*, vol. 62, pp. 50–60, 2018.

[7] G. Reddiconto, C. Toto, I. Palamà et al., “Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells,” *Blood*, vol. 119, no. 10, pp. 2335–2345, 2012.

[8] F. H. Heidel, L. Bullinger, Z. Feng et al., “Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML,” *Cell Stem Cell*, vol. 10, no. 4, pp. 412–424, 2012.

[9] M. Scheller, J. Schönheit, K. Zimmermann, U. Leser, F. Rosenbauer, and A. Leutz, “Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance,” *Journal of Experimental Medicine*, vol. 210, no. 11, pp. 2239–2256, 2013.

[10] C. Schürch, C. Riether, M. S. Matter, A. Tzankov, and A. F. Ochsenbein, “CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression,” *Journal of Clinical Investigation*, vol. 122, no. 2, pp. 624–638, 2012.

[11] N. Orsolic, M. Golemovic, A. Quintas-Cardama et al., “Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells,” *Cancer Science*, vol. 97, no. 9, pp. 952–960, 2006.

[12] S. Yousefnia, S. Momenzadeh, F. Seyed Forootan, K. Ghadi, and M. H. Nasr Esfahani, “The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity,” *Gene*, vol. 649, no. 649, pp. 14–22, 2018.
[13] X. Zuo, M. Xu, J. Yu et al., "Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-δ/β over-expression," Journal of the National Cancer Institute: Journal of the National Cancer Institute (1988), vol. 106, no. 4, Article ID dju052, 2014.

[14] A. Montagner, M. B. Delgado, C. Tallichet-Blanc et al., “Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer,” EMBO Molecular Medicine, vol. 6, no. 1, pp. 80–98, 2014.